Citations (109)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ru Han, Shuyao Liang, Clément François, Samuel Aballea, Emilie Clay & Mondher Toumi. (2021) Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach. Journal of Market Access & Health Policy 9:1.
Read now
Read now
Vijay Gayam, Benjamin Tiongson, Amrendra Kumar Mandal, Pavani Garlapati, Calvin Pan & Smruti Mohanty. (2019) Real-world study of hepatitis C treatment with direct-acting antivirals in patients with drug abuse and opioid agonist therapy. Scandinavian Journal of Gastroenterology 54:5, pages 646-655.
Read now
Read now
Articles from other publishers (107)
J.I. Tsui, A.J. Gojic, K.A. Pierce, E.L. Tung, N.C. Connolly, A.C. Radick, R.R. Hunt, R. Sandvold, K. Taber, M. Ninburg, R.H. Kubiniec, J.D. Scott, R.N. Hansen, J.D. Stekler, E.J. Austin, E.C. Williams & S.N. Glick. (2024) Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs. Drug and Alcohol Dependence Reports 10, pages 100213.
Crossref
Crossref
Catelyn R. Coyle, Rachel E. Gicquelais, Becky L. Genberg, Jacquie Astemborski, Oluwaseun Falade-Nwulia, Gregory D. Kirk, David L. Thomas & Shruti H. Mehta. (2023) Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals. Drug and Alcohol Dependence 253, pages 111007.
Crossref
Crossref
Marguerite E Beiser, Leah C Shaw, Savanna K Shores, Joanne M Carson & Behzad Hajarizadeh. (2023) Hepatitis C Virus Reinfection in a Real-World Cohort of Homeless-Experienced Individuals in Boston. Clinical Infectious Diseases 77:1, pages 46-55.
Crossref
Crossref
Tony Antoniou, Cheryl Pritlove, Dana Shearer, Mina Tadrous, Hemant Shah & Tara Gomes. (2023) Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study. International Journal for Equity in Health 22:1.
Crossref
Crossref
Haesuk Park, Carolyn Brown, Debbie L. Wilson, Pei-Lin Huang, Pilar Hernández-Con, Patrick Horne, Amie Goodin, Amanda Joseph, Rich Segal, Roniel Cabrera & Robert L. Cook. (2023) Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States. Preventive Medicine Reports 32, pages 102138.
Crossref
Crossref
Jim Young, Shouao Wang, Charlotte Lanièce Delaunay, Curtis L Cooper, Joseph Cox, M John Gill, Mark Hull, Sharon Walmsley, Alexander Wong & Marina B Klein. (2023) The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination. International Journal of Drug Policy 114, pages 103981.
Crossref
Crossref
Magdalena Ydreborg, Emil Lundström, Rosanna Kolleby, Sofia Lexén, Elena Pizarro, Jessica Lindgren, Rune Wejstål & Simon B. Larsson. (2023) Linkage to hepatitis C treatment in two opioid substitution treatment units in Gothenburg, Sweden: a retrospective cohort study. Substance Abuse Treatment, Prevention, and Policy 18:1.
Crossref
Crossref
Andrew H. Talal, Elisavet M. SofikitouKejia WangSuzanne DickersonUrmo JaanimägiMarianthi Markatou. (2023) High Satisfaction with Patient-Centered Telemedicine for Hepatitis C Virus Delivered to Substance Users: A Mixed-Methods Study. Telemedicine and e-Health 29:3, pages 395-407.
Crossref
Crossref
Nathalie Jiang, Julie Bruneau, Iuliia Makarenko, Nanor Minoyan, Geng Zang, Stine Bordier Høj, Sarah Larney & Valérie Martel-Laferrière. (2023) HCV treatment initiation in the era of universal direct acting antiviral coverage – Improvements in access and persistent barriers. International Journal of Drug Policy 113, pages 103954.
Crossref
Crossref
Roy Lothan, Noa Gutman & Dan Yamin. (2022) Country versus pharmaceutical company interests for hepatitis C treatment. Health Care Management Science 25:4, pages 725-749.
Crossref
Crossref
Alison D. Marshall, Marianne Martinello, Carla Treloar & Gail V. Matthews. (2022) Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission: The CEASE qualitative study. International Journal of Drug Policy 109, pages 103828.
Crossref
Crossref
Jason Grebely, Gregory J. DoreFrederick L. Altice, Brian ConwayAlain H. LitwinBrianna L. NortonOlav Dalgard, Edward J. GaneOren ShiboletRonald Nahass, Anne F. Luetkemeyer, Cheng-Yuan Peng, David IserIsaias Noel GendranoMichelle M. Kelly, Peggy Hwang, Ernest Asante-AppiahBarbara A. HaberEliav BarrMichael N. RobertsonHeather Platt. (2022) Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy. Annals of Internal Medicine 175:9, pages 1221-1229.
Crossref
Crossref
Jenny E. Ozga, Jennifer L. Syvertsen & Robin A. Pollini. (2022) Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California. Journal of Viral Hepatitis 29:7, pages 518-528.
Crossref
Crossref
Jui-Ting Hsu, Ping-I Hsu, Chang-Bih Shie, Seng-Kee Chuah, I-Ting Wu, Wen-Wei Huang, Sheng-Yeh Tang, Kun-Feng Tsai, Li-Fu Kuo, Supratip Ghose, Jui-Che Hsu & Chih-An Shih. (2022) Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users. Medicina 58:3, pages 436.
Crossref
Crossref
Kathleen M Ward, Oluwaseun Falade-Nwulia, Juhi Moon, Catherine G Sutcliffe, Sherilyn Brinkley, Taryn Haselhuhn, Stephanie Katz, Kayla Herne, Lilian Arteaga, Shruti H Mehta, Carl Latkin, Robert K Brooner & Mark S Sulkowski. (2022) Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs. The Journal of Infectious Diseases 225:5, pages 903-911.
Crossref
Crossref
Anishaa Sivakumar, Lynn Madden, Elizabeth DiDomizio, Anthony Eller, Merceditas Villanueva & Frederick L. Altice. (2022) Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. International Journal of Drug Policy 101, pages 103570.
Crossref
Crossref
Judith I. Tsui, Michael P. Barry, Elizabeth J. Austin, Elsa W. Sweek, Elyse Tung, Ryan N. Hansen, Michael Ninburg, John D. Scott, Sara N. Glick & Emily C. Williams. (2021) ‘Treat my whole person, not just my condition’: qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Addiction Science & Clinical Practice 16:1.
Crossref
Crossref
Trevor Goodyear, Helen Brown, Annette J. Browne, Peter Hoong, Lianping Ti & Rod Knight. (2021) “I want to get better, but…”: identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments. International Journal for Equity in Health 20:1.
Crossref
Crossref
Belle V. Ngo, Jocelyn R. James, Kendra L. Blalock, Sara L. Jackson, Lisa D. Chew & Judith I. Tsui. (2021) Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings. Journal of Substance Abuse Treatment 131, pages 108438.
Crossref
Crossref
Radha K. Dhiman, Gagandeep S. Grover, Madhumita Premkumar, Akash Roy, Sunil Taneja, Ajay Duseja & Sanjeev Arora. (2021) Outcomes of real-world integrated HCV microelimination for people who inject drugs: an expansion of the punjab model. eClinicalMedicine 41, pages 101148.
Crossref
Crossref
Xinyi JiangScott Martin VouriVakaramoko DiabyWeihsuan Lo-CiganicRobert ParkerHaesuk Park. (2021) Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C. Journal of Managed Care & Specialty Pharmacy 27:10, pages 1388-1402.
Crossref
Crossref
Jessica Jacob, Trevor Goodyear, Pierre-julien Coulaud, Peter Hoong, Lianping Ti & Rod Knight. (2021) “I want to feel young again”: experiences and perspectives of young people who inject drugs living with hepatitis C in Vancouver, Canada. Canadian Journal of Public Health 112:5, pages 947-956.
Crossref
Crossref
Peng Huang, Yan Wang, Ming Yue, Zhijun Ge, Xueshan Xia, Andre J. Jeyarajan, Jacinta A. Holmes, Rongbin Yu, Chuanwu Zhu, Sheng Yang, Wenyu Lin & Raymond T. Chung. (2021) The risk of hepatitis C virus recurrence in hepatitis C virus‐infected patients treated with direct‐acting antivirals after achieving a sustained virological response: A comprehensive analysis. Liver International 41:10, pages 2341-2357.
Crossref
Crossref
Megan Bardsley, Ellen Heinsbroek, Ross Harris, Sara Croxford, Claire Edmundson, Vivian Hope, Nasra Hassan, Samreen Ijaz, Sema Mandal, Justin Shute, Sharon J. Hutchinson, Matthew Hickman, Katy Sinka & Emily Phipps. (2021) The impact of direct‐acting antivirals on hepatitis C viraemia among people who inject drugs in England; real‐world data 2011–2018. Journal of Viral Hepatitis 28:10, pages 1452-1463.
Crossref
Crossref
Emmanuel Fortier, Stine Bordier Høj, Marie-Pierre Sylvestre, Andreea Adelina Artenie, Nanor Minoyan, Didier Jutras-Aswad, Jason Grebely & Julie Bruneau. (2021) Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada. International Journal of Drug Policy 96, pages 103439.
Crossref
Crossref
Joanne M. Carson, Behzad Hajarizadeh, Josh Hanson, James O'Beirne, David Iser, Phillip Read, Anne Balcomb, Jane Davies, Joseph S. Doyle, Jasmine Yee, Marianne Martinello, Philippa Marks, Gregory J. Dore & Gail V. Matthews. (2021) Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort. International Journal of Drug Policy 96, pages 103422.
Crossref
Crossref
Marion Selfridge, Evan B Cunningham, Tamara Barnett, Anne Drost, Christianne Gray-Schleihauf, Kellie Guarasci, Karen Lundgren, Roz Milne, Jason Grebely & Chris Fraser. (2021) Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada. International Journal of Drug Policy 96, pages 103418.
Crossref
Crossref
Trevor Goodyear, Helen Brown, Annette J. Browne, Peter Hoong, Lianping Ti & Rod Knight. (2021) “Stigma is where the harm comes from”: Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs. International Journal of Drug Policy 96, pages 103238.
Crossref
Crossref
Håvard Midgard, Kjersti Ulstein, Øystein Backe, Tarjei Foshaug, Hanne Sørli, Kristin Vennesland, David Nilssen, Elin Hoffmann Dahl, Ane-Kristine Finbråten, Linda Wüsthoff & Olav Dalgard. (2021) Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway. International Journal of Drug Policy 96, pages 103165.
Crossref
Crossref
Jennifer R. Eames & Bau Tran. (2021) Hepatitis C. Physician Assistant Clinics 6:4, pages 555-568.
Crossref
Crossref
Xinyi JiangHyun Jin SongWei WangLinda HenryLindsey M Childs-KeanVincent Lo ReIIIIIIHaesuk Park. (2021) The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders. Journal of Managed Care & Specialty Pharmacy 27:7, pages 873-881.
Crossref
Crossref
Brianna L. Norton, Matthew J. Akiyama, Julia H. Arnsten, Linda Agyemang, Moonseong Heo & Alain H. Litwin. (2021) High HCV cure rates among people who inject drugs and have suboptimal adherence: A patient-centered approach to HCV models of care. International Journal of Drug Policy 93, pages 103135.
Crossref
Crossref
Evan B Cunningham, Behzad Hajarizadeh, Janaki Amin, Margaret Hellard, Julie Bruneau, Jordan J Feld, Curtis Cooper, Jeff Powis, Alain H Litwin, Philippa Marks, Olav Dalgard, Brian Conway, Alberto Moriggia, Catherine Stedman, Phillip Read, Philip Bruggmann, Karine Lacombe, Adrian Dunlop, Tanya L Applegate, Gail V Matthews, Chris Fraser, Gregory J Dore & Jason Grebely. (2021) Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. Clinical Infectious Diseases 72:8, pages 1392-1400.
Crossref
Crossref
Chunki Fong, Pedro Mateu-Gelabert, Courtney Ciervo, Benjamin Eckhardt, Yesenia Aponte-Melendez, Shashi Kapadia & Kristen Marks. (2021) Medical provider stigma experienced by people who use drugs (MPS-PWUD): Development and validation of a scale among people who currently inject drugs in New York City. Drug and Alcohol Dependence 221, pages 108589.
Crossref
Crossref
Kimberly PageMichael T. MeliaRebecca T. VeenhuisMatthew WinterKimberly E. Rousseau, Guido MassaccesiWilliam O. OsburnMichael FormanElaine ThomasKarla ThorntonKatherine WagnerVentzislav VassilevLan LinPaula J. LumLinda C. GiudiceEllen SteinAlice AsherSoju ChangRichard GormanMarc G. GhanyT. Jake LiangMichael R. WierzbickiElisa ScarselliAlfredo NicosiaAntonella FolgoriStefania CaponeAndrea L. Cox. (2021) Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. New England Journal of Medicine 384:6, pages 541-549.
Crossref
Crossref
Ping Du, Xi Wang, Lan Kong, Thomas RileyIIIIII & Jeah Jung. (2021) Changing Urban–Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014–2017. American Journal of Preventive Medicine 60:2, pages 285-293.
Crossref
Crossref
Haesuk Park, Hyun Jin Song, Xinyi Jiang, Linda Henry, Robert L. Cook & David R. Nelson. (2020) Direct‐Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C. Hepatology Communications 5:2, pages 203-216.
Crossref
Crossref
Irene Pericot-Valverde, Divya Ahuja, Brianna L. Norton & Alain H. Litwin. 2021. The Opioid Epidemic and Infectious Diseases. The Opioid Epidemic and Infectious Diseases
77
96
.
Geert Robaeys & Rob Bielen. 2021. Hepatitis C: Care and Treatment. Hepatitis C: Care and Treatment
191
211
.
Vincenzo Messina, Lorenzo Onorato, Giovanni Di Caprio, Ernesto Claar, Vincenzo Iovinella, Antonio Russo, Valerio Rosato, Angela Salzillo, Riccardo Nevola, Filomena Simeone, Fabio Curcio, Mariantonietta Pisaturo & Nicola Coppola. (2020) Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. Life 11:1, pages 17.
Crossref
Crossref
Jacqueline E. Sherbuk, Alexa Tabackman, Kathleen A. McManus, Terry Kemp Knick, Julie Schexnayder, Tabor E. Flickinger & Rebecca Dillingham. (2020) A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South. Harm Reduction Journal 17:1.
Crossref
Crossref
Anna Versfeld, Angela McBride, Andrew Scheibe & C. Wendy Spearman. (2020) Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities. Harm Reduction Journal 17:1.
Crossref
Crossref
Oluwaseun Falade‐Nwulia, Rachel E. Gicquelais, Jacquie Astemborski, Sean D. McCormick, Greg Kirk, Mark Sulkowski, David L. Thomas & Shruti H. Mehta. (2020) Hepatitis C treatment uptake among people who inject drugs in the oral direct‐acting antiviral era. Liver International 40:10, pages 2407-2416.
Crossref
Crossref
Jacqueline E Sherbuk, Terry Kemp Knick, Chelsea Canan, Patrice Ross, Bailey Helbert, Eleanor Sue Cantrell, Charlene Joie Cantrell, Rachel Stallings, Nicole Barron, Diana Jordan, Kathleen A McManus & Rebecca Dillingham. (2020) Development of an Interdisciplinary Telehealth Model of Provider Training and Comprehensive Care for Hepatitis C and Opioid Use Disorder in a High-Burden Region. The Journal of Infectious Diseases 222:Supplement_5, pages S354-S364.
Crossref
Crossref
Samira Hosseini-Hooshyar, Marianne Martinello, Jasmine Yee, Phillip Read, David Baker, Jeffrey J. Post, Robert Finlayson, Mark Bloch, Joseph S. Doyle, David ShawMargaret Hellard, Kathy Petoumenos, Joanne Carson, Gregory J. Dore & Gail V. Matthews. (2020) Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV. AIDS 34:9, pages 1347-1358.
Crossref
Crossref
Abbe Muller, David Vlahov, Matthew J. Akiyama & Ann Kurth. (2020) Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis. International Journal of Environmental Research and Public Health 17:14, pages 4951.
Crossref
Crossref
Trevor Goodyear, Lianping Ti, Patrizia Carrieri, Will Small & Rod Knight. (2020) “Everybody living with a chronic disease is entitled to be cured”: Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. International Journal of Drug Policy 81, pages 102766.
Crossref
Crossref
Mark Sulkowski, Annie F. Luetkemeyer, David L. Wyles, Claudia Martorell, Andrew Muir, Ilan Weisberg, Stuart C. Gordon, Richard McLain & Gregory Huhn. (2020) Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non‐adherence. Alimentary Pharmacology & Therapeutics 51:12, pages 1384-1396.
Crossref
Crossref
Marianne Martinello, Sahar Bajis & Gregory J. Dore. (2020) Progress Toward Hepatitis C Virus Elimination. Gastroenterology Clinics of North America 49:2, pages 253-277.
Crossref
Crossref
Christiana Graf, Marcus M Mücke, Georg Dultz, Kai-Henrik Peiffer, Alica Kubesch, Patrick Ingiliz, Stefan Zeuzem, Eva Herrmann & Johannes Vermehren. (2020) Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis. Clinical Infectious Diseases 70:11, pages 2355-2365.
Crossref
Crossref
Andreea A Artenie, Evan B Cunningham, Gregory J Dore, Brian Conway, Olav Dalgard, Jeff Powis, Philip Bruggmann, Margaret Hellard, Curtis Cooper, Philip Read, Jordan J Feld, Behzad Hajarizadeh, Janaki Amin, Karine Lacombe, Catherine Stedman, Alain H Litwin, Pip Marks, Gail V Matthews, Sophie Quiene, Amanda Erratt, Julie Bruneau & Jason Grebely. (2020) Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. Clinical Infectious Diseases 70:11, pages 2369-2376.
Crossref
Crossref
Behzad Hajarizadeh, Evan B. Cunningham, Heather Valerio, Marianne Martinello, Matthew Law, Naveed Z. Janjua, Håvard Midgard, Olav Dalgard, John Dillon, Matthew Hickman, Julie Bruneau, Gregory J. Dore & Jason Grebely. (2020) Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology 72:4, pages 643-657.
Crossref
Crossref
Jason Grebely & Marianne Martinello. 2020. Clinical Dilemmas in Viral Liver Disease. Clinical Dilemmas in Viral Liver Disease
106
111
.
Sahar Bajis, Jason Grebely, Behzad Hajarizadeh, Tanya Applegate, Alison D. Marshall, Mary Ellen Harrod, Jude Byrne, Nicky Bath, Phillip Read, Michael Edwards, Carla Gorton, Jeremy Hayllar, Victoria Cock, Steven Peterson, Claire Thomson, Martin Weltman, Meryem Jefferies, William Wood, Paul Haber, Nadine Ezard, Marianne Martinello, Lisa Maher & Gregory J. Dore. (2019) Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre‐ and post‐universal access to direct‐acting antiviral treatment in Australia: The LiveRLife study. Journal of Viral Hepatitis 27:3, pages 281-293.
Crossref
Crossref
Aysegul Erman, William W. L. Wong, Jordan J. Feld, Paul Grootendorst & Murray D. Krahn. (2019) The health impact of delaying direct‐acting antiviral treatment for chronic hepatitis C: A decision‐analytic approach. Liver International 40:1, pages 51-59.
Crossref
Crossref
Avni Mittal, Karen C. Kosinski & Thomas J. Stopka. (2019) HCV treatment access among Latinxs who inject drugs: qualitative findings from Boston, Massachusetts, 2016. Harm Reduction Journal 16:1.
Crossref
Crossref
Ellen Childs, Sabrina A. Assoumou, Katie B. Biello, Dea L. Biancarelli, Mari-Lynn Drainoni, Alberto Edeza, Peter Salhaney, Matthew J. Mimiaga & Angela R. Bazzi. (2019) Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs. Harm Reduction Journal 16:1.
Crossref
Crossref
Patrick Ingiliz & Frank Tacke. (2019) How effective and how durable is DAA‐therapy in HCV‐infected drug users?. Liver International 39:12, pages 2238-2239.
Crossref
Crossref
Ned H. Latham, Joseph S. Doyle, Anna Y. Palmer, Joost W. Vanhommerig, Paul Agius, Stelliana Goutzamanis, Zinia Li, Alisa Pedrana, Magnus Gottfredsson, Julie Bouscaillou, Niklas Luhmann, Alyona Mazhnaya, Frederick L. Altice, Sahar Saeed, Marina Klein, Oluwaseun O. Falade‐Nwulia, Esther Aspinall, Sharon Hutchinson, Margaret E. Hellard & Rachel Sacks‐Davis. (2019) Staying hepatitis C negative: A systematic review and meta‐analysis of cure and reinfection in people who inject drugs. Liver International 39:12, pages 2244-2260.
Crossref
Crossref
Phillip Read, Rosie Gilliver, John Kearley, Rebecca Lothian, Evan B. Cunningham, Karen J. Chronister & Gregory J. Dore. (2019) Treatment adherence and support for people who inject drugs taking direct‐acting antiviral therapy for hepatitis C infection. Journal of Viral Hepatitis 26:11, pages 1301-1310.
Crossref
Crossref
Julie Holeksa, Tianna Magel, Arshia Alimohammadi, Astou Thiam, Rossitta Yung, Letitia Chu, David Truong & Brian Conway. (2019) Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada. International Journal of Drug Policy 72, pages 177-180.
Crossref
Crossref
M. Eugenia Socías, Mohammad Karamouzian, Stephanie Parent, José Barletta, Kathleen Bird & Lianping Ti. (2019) Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review. International Journal of Drug Policy 72, pages 146-159.
Crossref
Crossref
Iuliia Makarenko, Adelina Artenie, Stine Hoj, Nanor Minoyan, Brendan Jacka, Geng Zang, Gillian Barlett, Didier Jutras-Aswad, Valerie Martel-Laferriere & Julie Bruneau. (2019) Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?. International Journal of Drug Policy 72, pages 69-76.
Crossref
Crossref
Stine Bordier Høj, Brendan Jacka, Nanor Minoyan, Andreea Adelina Artenie & Julie Bruneau. (2019) Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs. International Journal of Drug Policy 72, pages 11-23.
Crossref
Crossref
Marion Selfridge, Evan B. Cunningham, Rozalyn Milne, Anne Drost, Tamara Barnett, Karen Lundgren, Kellie Guarasci, Jason Grebely & Chris Fraser. (2019) Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada. International Journal of Drug Policy 72, pages 106-113.
Crossref
Crossref
Desmond Crowley, Walter Cullen, John S. Lambert & Marie Claire Van Hout. (2019) Competing priorities and second chances - A qualitative exploration of prisoners’ journeys through the Hepatitis C continuum of care. PLOS ONE 14:9, pages e0222186.
Crossref
Crossref
Alain H. Litwin, Martine Drolet, Chizoba Nwankwo, Martha Torrens, Andrej Kastelic, Stephan Walcher, Lorenzo Somaini, Emily Mulvihill, Jochen Ertl & Jason Grebely. (2019) Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C‐SCOPE Study. Journal of Viral Hepatitis 26:9, pages 1094-1104.
Crossref
Crossref
Sabrina Molinaro, Giuliano Resce, Alfredo Alberti, Massimo Andreoni, Pietro P. F. D′Egidio, Claudio Leonardi, Felice A. Nava, Patrizio Pasqualetti & Stefano Villa. (2019) Barriers to effective management of hepatitis C virus in people who inject drugs: Evidence from outpatient clinics. Drug and Alcohol Review 38:6, pages 644-655.
Crossref
Crossref
Audun J. Lier, Kalie Smith, Kerim Odekon, Silvia Bronson, Erin Taub, Mathew Tharakan, Gerald J. Kelly, Pruthvi Patel & Luis A. Marcos. (2019) Risk Factors Associated with Linkage to Care among Suburban Hepatitis C-Positive Baby Boomers and Injection Drug Users. Infectious Diseases and Therapy 8:3, pages 417-428.
Crossref
Crossref
M. Eugenia Socías, Lianping Ti, Evan Wood, Ekaterina Nosova, Mark Hull, Kanna Hayashi, Kora Debeck & M‐J Milloy. (2019) Disparities in uptake of direct‐acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting. Liver International 39:8, pages 1400-1407.
Crossref
Crossref
A Rivero‐Juarez, F Tellez, M Castaño‐Carracedo, D Merino, N Espinosa, J Santos, J Macias, M Paniagua‐García, A Zapata‐Lopez, A Collado, MA Gómez‐Vidal, J Perez‐Stachowski, L Muñoz‐Medina, E Fernandez‐Fuertes & A Rivero. (2019)
Parenteral drug use as the main barrier to hepatitis C treatment uptake in
HIV
‐infected patients
. HIV Medicine 20:6, pages 359-367.
Crossref
Crossref
Jorge Mera, Kartik Joshi, Karla Thornton, Terry Box, John Scott, Miranda Sedillo, Paulina Deming, Crystal David, Whitney Essex, Richard Manch & Anita Kohli. (2019) Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian/Alaskan Natives. Open Forum Infectious Diseases 6:7.
Crossref
Crossref
Juan Macías, Luis E. Morano, Francisco Téllez, Rafael Granados, Antonio Rivero-Juárez, Rosario Palacios, MªJosé Ríos, Dolores Merino, Montserrat Pérez-Pérez, Antonio Collado, Blanca Figueruela, Aitana Morano, Carolina Freyre-Carrillo, José M. Martín, Antonio Rivero, Federico García & Juan A. Pineda. (2019) Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. Journal of Hepatology 71:1, pages 45-51.
Crossref
Crossref
Peter Ferenci, Stefan Bourgeois, Peter Buggisch, Suzanne Norris, Manuela Curescu, Dominique Larrey, Fiona Marra, Henning Kleine, Patrick Dorr, Mariem Charafeddine, Eric Crown, Mark Bondin, David Back & Robert Flisiak. (2019) Real‐world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1‐ and 4‐infected patients with diverse comorbidities and comedications: A pooled analysis of post‐marketing observational studies from 13 countries. Journal of Viral Hepatitis 26:6, pages 685-696.
Crossref
Crossref
Christian B. Ramers, Jie Liu & Catherine Frenette. (2019) Barriers to Treatment of Hepatitis C Virus in the Direct-Acting Antiviral Era. Current Treatment Options in Infectious Diseases 11:2, pages 92-102.
Crossref
Crossref
Desarae Echevarria, Alexander Gutfraind, Basmattee Boodram, Jennifer Layden, Jonathan Ozik, Kimberly Page, Scott J. Cotler, Marian Major & Harel Dahari. (2019) Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago. Vaccine 37:19, pages 2608-2616.
Crossref
Crossref
Oluwaseun Falade-Nwulia, Risha Irvin, Alana Merkow, Mark Sulkowski, Alexander Niculescu, Yngvild Olsen, Kenneth Stoller, David L. Thomas, Carl Latkin & Shruti H. Mehta. (2019) Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. Journal of Substance Abuse Treatment 100, pages 45-51.
Crossref
Crossref
Jason Grebely, Gregory J. Dore, Negar N. Alami, Brian Conway, John F. Dillon, Michael Gschwantler, Franco Felizarta, Christophe Hézode, Krzysztof Tomasiewicz, Linda M. Fredrick, Emily O. Dumas & Federico J. Mensa. (2019) Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy. International Journal of Drug Policy 66, pages 73-79.
Crossref
Crossref
Roy Nitulescu, Jim Young, Sahar Saeed, Curtis Cooper, Joseph Cox, Valerie Martel-Laferriere, Mark Hull, Sharon Walmsley, Mark Tyndall, Alexander Wong & Marina B. Klein. (2019) Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. International Journal of Drug Policy 65, pages 41-49.
Crossref
Crossref
Judith I. Tsui, Claire M. Miller, John D. Scott, Maria A. Corcorran, Julia C. Dombrowski & Sara N. Glick. (2019) Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle. Drug and Alcohol Dependence 195, pages 114-120.
Crossref
Crossref
Jenny Iversen, Gregory J. Dore, Beth Catlett, Philip Cunningham, Jason Grebely & Lisa Maher. (2019) Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. Journal of Hepatology 70:1, pages 33-39.
Crossref
Crossref
Jason Grebely, Martine Drolet, Chizoba Nwankwo, Martha Torrens, Andrej Kastelic, Stephan Walcher, Lorenzo Somaini, Emily Mulvihill, Jochen Ertl, Ryan Liebert & Alain H. Litwin. (2019) Perceptions and self-reported competency related to testing, management and treatment of hepatitis C virus infection among physicians prescribing opioid agonist treatment: The C-SCOPE study. International Journal of Drug Policy 63, pages 29-38.
Crossref
Crossref
Marianne Martinello, Behzad Hajarizadeh, Jason Grebely, Gail V. Matthews & Gregory J. Dore. 2019. HCV: The Journey from Discovery to a Cure. HCV: The Journey from Discovery to a Cure
447
490
.
Jason Grebely, Massimo Puoti, Heiner Wedemeyer, Curtis Cooper, Mark S Sulkowski, Graham R Foster, Thomas Berg, Erica Villa, Federico Rodriguez-Perez, David L Wyles, Gretja Schnell, Negar N Alami, Zhenzhen Zhang, Emily Dumas & Gregory J Dore. (2018) Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. Open Forum Infectious Diseases 5:11.
Crossref
Crossref
Carmine Rossi, Zahid A. Butt, Stanley Wong, Jane A. Buxton, Nazrul Islam, Amanda Yu, Maryam Darvishian, Mark Gilbert, Jason Wong, Nuria Chapinal, Mawuena Binka, Maria Alvarez, Mark W. Tyndall, Mel Krajden & Naveed Z. Janjua. (2018) Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort. Journal of Hepatology 69:5, pages 1007-1014.
Crossref
Crossref
Alison D. Marshall, Jean-Michel Pawlotsky, Jeffrey V. Lazarus, Alessio Aghemo, Gregory J. Dore & Jason Grebely. (2018) The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. Journal of Hepatology 69:5, pages 1188-1196.
Crossref
Crossref
Behzad Hajarizadeh, Evan B Cunningham, Hannah Reid, Matthew Law, Gregory J Dore & Jason Grebely. (2018) Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 3:11, pages 754-767.
Crossref
Crossref
Susan Nouch, Lesley Gallagher, Margaret Erickson, Rabab Elbaharia, Wendy Zhang, Lu Wang, Nic Bacani, Deborah Kason, Holly Kleban, Laura Knebel, David Hall, Rolando Barrios & Mark Hull. (2018) Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada. International Journal of Drug Policy 59, pages 76-84.
Crossref
Crossref
Leah M. AdamsBenjamin BaldersonBruce J. PackettIIII. (2018) Meeting the Challenge: Hepatitis C Virus and HIV Care Experiences Among HIV Specialty Providers. AIDS Patient Care and STDs 32:8, pages 314-320.
Crossref
Crossref
Eshan U. Patel, Sunil S. Solomon, Allison M. Mcfall, Aylur K. Srikrishnan, Amrose Pradeep, Paneerselvam Nandagopal, Oliver Laeyendecker, Aaron A.R. Tobian, David L. Thomas, Mark S. Sulkowski, M. Suresh Kumar & Shruti H. Mehta. (2018) Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India. International Journal of Drug Policy 57, pages 51-60.
Crossref
Crossref
Meredith E. Clement, Lauren F. Collins, Julius M. Wilder, Michael Mugavero, Taryn Barker & Susanna Naggie. (2018) Hepatitis C Virus Elimination in the Human Immunodeficiency Virus–Coinfected Population. Infectious Disease Clinics of North America 32:2, pages 407-423.
Crossref
Crossref
Marianne Martinello, Gregory J. Dore, Gail V. Matthews & Jason Grebely. (2018) Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. Infectious Disease Clinics of North America 32:2, pages 371-393.
Crossref
Crossref
Asher J. Schranz, Jessica Barrett, Christopher B. Hurt, Carlos Malvestutto & William C. Miller. (2018) Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C. Current HIV/AIDS Reports 15:3, pages 245-254.
Crossref
Crossref
Cara L. McDermott, Catherine M. Lockhart & Beth Devine. (2018) Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis. Journal of Virus Eradication 4:2, pages 118-122.
Crossref
Crossref
O. Falade‐Nwulia, M. S. Sulkowski, A. Merkow, C. Latkin & S. H. Mehta. (2018) Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral era. Journal of Viral Hepatitis 25:3, pages 220-227.
Crossref
Crossref
Jason Grebely, Olav Dalgard, Brian Conway, Evan B Cunningham, Philip Bruggmann, Behzad Hajarizadeh, Janaki Amin, Julie Bruneau, Margaret Hellard, Alain H Litwin, Philippa Marks, Sophie Quiene, Sharmila Siriragavan, Tanya L Applegate, Tracy Swan, Jude Byrne, Melanie Lacalamita, Adrian Dunlop, Gail V Matthews, Jeff Powis, David Shaw, Maria Christine Thurnheer, Martin Weltman, Ian Kronborg, Curtis Cooper, Jordan J Feld, Chris Fraser, John F Dillon, Phillip Read, Ed Gane & Gregory J Dore. (2018) Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. The Lancet Gastroenterology & Hepatology 3:3, pages 153-161.
Crossref
Crossref
Jason Grebely, Jordan J Feld, David Wyles, Mark Sulkowski, Liyun Ni, Joe Llewellyn, Heshaam M Mir, Nika Sajed, Luisa M Stamm, Robert H Hyland, John McNally, Diana M Brainard, Ira Jacobson, Stefan Zeuzem, Marc Bourlière, Graham Foster, Nezam Afdhal & Gregory J Dore. (2018) Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. Open Forum Infectious Diseases 5:2.
Crossref
Crossref
Alison D Marshall, Evan B Cunningham, Stine Nielsen, Alessio Aghemo, Hannu Alho, Markus Backmund, Philip Bruggmann, Olav Dalgard, Carole Seguin-Devaux, Robert Flisiak, Graham R Foster, Liana Gheorghe, David Goldberg, Ioannis Goulis, Matthew Hickman, Patrick Hoffmann, Ligita Jancorienė, Peter Jarcuska, Martin Kåberg, Leondios G Kostrikis, Mihály Makara, Matti Maimets, Rui Tato Marinho, Mojca Matičič, Suzanne Norris, Sigurður Ólafsson, Anne Øvrehus, Jean-Michel Pawlotsky, James Pocock, Geert Robaeys, Carlos Roncero, Marieta Simonova, Jan Sperl, Michele Tait, Ieva Tolmane, Stefan Tomaselli, Marc van der Valk, Adriana Vince, Gregory J Dore, Jeffrey V Lazarus & Jason Grebely. (2018) Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. The Lancet Gastroenterology & Hepatology 3:2, pages 125-133.
Crossref
Crossref
Jason Grebely, Behzad Hajarizadeh & Gregory J. Dore. (2017) Direct-acting antiviral agents for HCV infection affecting people who inject drugs. Nature Reviews Gastroenterology & Hepatology 14:11, pages 641-651.
Crossref
Crossref
Jason Grebely, Julie Bruneau, Philip Bruggmann, Magdalena Harris, Matthew Hickman, Tim Rhodes & Carla Treloar. (2017) Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. International Journal of Drug Policy 47, pages 26-33.
Crossref
Crossref
J.V. Lazarus, K. Safreed-Harmon, S.R. Stumo, M. Jauffret-Roustide, M. Maticic, T. Reic, E. Schatz, J. Tallada & M. Harris. (2017) Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses. International Journal of Drug Policy 47, pages 47-50.
Crossref
Crossref
N. Z. Janjua, N. Islam, J. Wong, E. M. Yoshida, A. Ramji, H. Samji, Z. A. Butt, M. Chong, D. Cook, M. Alvarez, M. Darvishian, M. Tyndall & M. Krajden. (2017)
Shift in disparities in hepatitis C treatment from interferon to
DAA
era: A population‐based cohort study
. Journal of Viral Hepatitis 24:8, pages 624-630.
Crossref
Crossref
Rob Bielen, Christophe Moreno, Hans Van Vlierberghe, Stefan Bourgeois, Jean-Pierre Mulkay, Thomas Vanwolleghem, Wim Verlinden, Christian Brixko, Jochen Decaestecker, Chantal De Galocsy, Filip Janssens, Mike Cool, Lode Van Overbeke, Christophe Van Steenkiste, François D'heygere, Wilfried Cools, Frederik Nevens & Geert Robaeys. (2017) Belgian experience with direct acting antivirals in people who inject drugs. Drug and Alcohol Dependence 177, pages 214-220.
Crossref
Crossref
Marianne Martinello, Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore & Gail V. Matthews. (2017) HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs. Current HIV/AIDS Reports 14:3, pages 110-121.
Crossref
Crossref
M. Martinello, J. Grebely, K. Petoumenos, E. Gane, M. Hellard, D. Shaw, J. Sasadeusz, T. L. Applegate, G. J. Dore & G. V. Matthews. (2017)
HCV
reinfection incidence among individuals treated for recent infection
. Journal of Viral Hepatitis 24:5, pages 359-370.
Crossref
Crossref
Benjamin Eckhardt. (2016) Hepatitis C Treatment in People Who Inject Drugs. Current Treatment Options in Infectious Diseases 8:4, pages 416-425.
Crossref
Crossref
Haesuk Park, Carolyn Brown, Debbie L. Wilson, Pei-Lin Huang, Pilar Hernandez-Con, Patrick Horne, Amie Goodin, Amanda Joseph, Rich Segal, Roniel Cabrera & Robert L. Cook. (2022) Clinician Barriers, Perceptions, and Practices in Treating Patients with Hepatitis C Virus and Substance Use Disorder. SSRN Electronic Journal.
Crossref
Crossref